BioCentury | Jan 4, 2020
Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

...the target, IMAB027, in a Phase I/II ovarian cancer study. Chinese CAR T cell company CARsgen Therapeutics Co. Ltd....
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...data for either will be presented at the meeting ( TPS8576 ). Bellicum Pharmaceuticals Inc., CARsgen Therapeutics Co. Ltd....
...was acquired by Celgene Corp. in 2018. Bellicum’s CAR targets PSCA to treat prostate cancer; CARsgen’s...
...Thousand Oaks, Calif. Baylor College of Medicine, Houston, Texas Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM), Houston, Texas CARsgen Therapeutics Co. Ltd....
BioCentury | Mar 8, 2019
Company News

CARsgen's BCMA CAR T moving to clinic in China

...CARsgen said CT053 (CAR-BCMA) received IND clearance from China's National Medical Products Administration (NMPA). CARsgen Therapeutics Co. Ltd. (Shanghai...
...member 17; TNFRSF17; CD269), is in development to treat relapsed/refractory multiple myeloma. Chris Lieu, Staff Writer CAR-BCMA, CT053 CARsgen Therapeutics Co. Ltd. Multiple...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...SRNE) Anti-CEA CAR-T Liver metasteses of colorectal and pancreatic cancer Ph I Claudin 18 (CLDN18) CARsgen Therapeutics Co. Ltd....
...EGFR Seattle Children's Hospital EGFR806 CAR T cells Brain cancer Ph I Glypican 3 (GPC3) CARsgen Therapeutics Co. Ltd....
BioCentury | Nov 2, 2018
Clinical News

BCMA race heats up as ASH abstracts released

...with GenScript subsidiaries Legend Biotech USA Inc. and Legend Biotech Ireland Ltd. to treat MM. CARsgen Therapeutics Co. Ltd....
...Summit, N.J. GenScript Biotech Corp. (HKSE:1548), Piscataway, N.J. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. CARsgen Therapeutics Co. Ltd....
...data Milestone: NA Brian Moy AMG 420, BI 836909 bb21217 J6M0-mcMMAF (2857916, GSK2857916) JCARH125 JNJ-68284528 (LCAR-B38M) PF-06863135 American Society of Hematology Amgen Inc. ASH bluebird bio Inc. CARsgen Therapeutics Co. Ltd. Celgene...
BioCentury | Nov 1, 2018
Clinical News

BCMA race heats up as ASH abstracts released

...and Legend Biotech Ireland Ltd. to treat MM. GenScript added HK$0.56 to HK$12.52 on Thursday. CARsgen Therapeutics Co. Ltd....
...in San Diego. Brian Moy AMG 420, BI 836909 bb21217 J6M0-mcMMAF (2857916, GSK2857916) JCARH125 JNJ-68284528 (LCAR-B38M) PF-06863135 American Society of Hematology Amgen Inc. ASH bluebird bio Inc. CARsgen Therapeutics Co. Ltd. Celgene...
BioCentury | Sep 14, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

...trial in collaboration with CARsgen. Data were presented at the 2018 CAR-TCR Summit in Boston. CARsgen...
...T cell therapy. The company developed the product in collaboration with the Shanghai Cancer Institute. CARsgen...
...for glioblastoma, and glypican 3 (GPC3) for hepatocellular carcinoma (HCC) and squamous cell lung cancer. CARsgen Therapeutics Co. Ltd....
BioCentury | Sep 10, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

...collaboration with CARsgen. Data were presented last week at the 2018 CAR-TCR Summit in Boston. CARsgen...
...T cell therapy. The company developed the product in collaboration with the Shanghai Cancer Institute. CARsgen...
...for glioblastoma, and glypican 3 (GPC3) for hepatocellular carcinoma (HCC) and squamous cell lung cancer. Allison Johnson CARsgen Therapeutics Co. Ltd. Shanghai...
BioCentury | May 16, 2018
Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

...a CAR T cell therapy against EGFRvIII, in Phase I/II testing to treat brain cancer. CARsgen Therapeutics Co. Ltd....
BioCentury | May 11, 2018
Financial News

ICT announces $28.3M series B round

...Therapeutics (Shanghai) Co. Ltd. (Shanghai, China) raised $90 million in a series A round, and CARsgen Therapeutics Co. Ltd....
Items per page:
1 - 10 of 23
BioCentury | Jan 4, 2020
Tools & Techniques

BioNTech tackles solid tumors by pairing CAR Ts with RNA vaccines

...the target, IMAB027, in a Phase I/II ovarian cancer study. Chinese CAR T cell company CARsgen Therapeutics Co. Ltd....
BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

...data for either will be presented at the meeting ( TPS8576 ). Bellicum Pharmaceuticals Inc., CARsgen Therapeutics Co. Ltd....
...was acquired by Celgene Corp. in 2018. Bellicum’s CAR targets PSCA to treat prostate cancer; CARsgen’s...
...Thousand Oaks, Calif. Baylor College of Medicine, Houston, Texas Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM), Houston, Texas CARsgen Therapeutics Co. Ltd....
BioCentury | Mar 8, 2019
Company News

CARsgen's BCMA CAR T moving to clinic in China

...CARsgen said CT053 (CAR-BCMA) received IND clearance from China's National Medical Products Administration (NMPA). CARsgen Therapeutics Co. Ltd. (Shanghai...
...member 17; TNFRSF17; CD269), is in development to treat relapsed/refractory multiple myeloma. Chris Lieu, Staff Writer CAR-BCMA, CT053 CARsgen Therapeutics Co. Ltd. Multiple...
BioCentury | Dec 21, 2018
Product R&D

Cell therapies seek solid ground

...SRNE) Anti-CEA CAR-T Liver metasteses of colorectal and pancreatic cancer Ph I Claudin 18 (CLDN18) CARsgen Therapeutics Co. Ltd....
...EGFR Seattle Children's Hospital EGFR806 CAR T cells Brain cancer Ph I Glypican 3 (GPC3) CARsgen Therapeutics Co. Ltd....
BioCentury | Nov 2, 2018
Clinical News

BCMA race heats up as ASH abstracts released

...with GenScript subsidiaries Legend Biotech USA Inc. and Legend Biotech Ireland Ltd. to treat MM. CARsgen Therapeutics Co. Ltd....
...Summit, N.J. GenScript Biotech Corp. (HKSE:1548), Piscataway, N.J. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. CARsgen Therapeutics Co. Ltd....
...data Milestone: NA Brian Moy AMG 420, BI 836909 bb21217 J6M0-mcMMAF (2857916, GSK2857916) JCARH125 JNJ-68284528 (LCAR-B38M) PF-06863135 American Society of Hematology Amgen Inc. ASH bluebird bio Inc. CARsgen Therapeutics Co. Ltd. Celgene...
BioCentury | Nov 1, 2018
Clinical News

BCMA race heats up as ASH abstracts released

...and Legend Biotech Ireland Ltd. to treat MM. GenScript added HK$0.56 to HK$12.52 on Thursday. CARsgen Therapeutics Co. Ltd....
...in San Diego. Brian Moy AMG 420, BI 836909 bb21217 J6M0-mcMMAF (2857916, GSK2857916) JCARH125 JNJ-68284528 (LCAR-B38M) PF-06863135 American Society of Hematology Amgen Inc. ASH bluebird bio Inc. CARsgen Therapeutics Co. Ltd. Celgene...
BioCentury | Sep 14, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

...trial in collaboration with CARsgen. Data were presented at the 2018 CAR-TCR Summit in Boston. CARsgen...
...T cell therapy. The company developed the product in collaboration with the Shanghai Cancer Institute. CARsgen...
...for glioblastoma, and glypican 3 (GPC3) for hepatocellular carcinoma (HCC) and squamous cell lung cancer. CARsgen Therapeutics Co. Ltd....
BioCentury | Sep 10, 2018
Clinical News

CARsgen solid tumor CAR T leads to complete response

...collaboration with CARsgen. Data were presented last week at the 2018 CAR-TCR Summit in Boston. CARsgen...
...T cell therapy. The company developed the product in collaboration with the Shanghai Cancer Institute. CARsgen...
...for glioblastoma, and glypican 3 (GPC3) for hepatocellular carcinoma (HCC) and squamous cell lung cancer. Allison Johnson CARsgen Therapeutics Co. Ltd. Shanghai...
BioCentury | May 16, 2018
Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

...a CAR T cell therapy against EGFRvIII, in Phase I/II testing to treat brain cancer. CARsgen Therapeutics Co. Ltd....
BioCentury | May 11, 2018
Financial News

ICT announces $28.3M series B round

...Therapeutics (Shanghai) Co. Ltd. (Shanghai, China) raised $90 million in a series A round, and CARsgen Therapeutics Co. Ltd....
Items per page:
1 - 10 of 23